These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38454481)

  • 21. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
    Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
    Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.
    Serrero G; Hawkins DM; Yue B; Ioffe O; Bejarano P; Phillips JT; Head JF; Elliott RL; Tkaczuk KR; Godwin AK; Weaver J; Kim WE
    Breast Cancer Res; 2012 Feb; 14(1):R26. PubMed ID: 22316048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
    Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
    Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
    Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
    J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
    Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
    Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
    Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
    Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
    Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm.
    Glinsky GV; Higashiyama T; Glinskii AB
    Clin Cancer Res; 2004 Apr; 10(7):2272-83. PubMed ID: 15073102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy.
    Tang J; Cui Q; Zhang D; Kong D; Liao X; Ren J; Gong Y; Wu G
    J Cell Physiol; 2020 May; 235(5):4746-4755. PubMed ID: 31663114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    Lindström LS; Yau C; Czene K; Thompson CK; Hoadley KA; Van't Veer LJ; Balassanian R; Bishop JW; Carpenter PM; Chen YY; Datnow B; Hasteh F; Krings G; Lin F; Zhang Y; Nordenskjöld B; Stål O; Benz CC; Fornander T; Borowsky AD; Esserman LJ;
    J Natl Cancer Inst; 2018 Jul; 110(7):726-733. PubMed ID: 29361175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
    Yu KD; Wu J; Shen ZZ; Shao ZM
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.
    Martin KJ; Patrick DR; Bissell MJ; Fournier MV
    PLoS One; 2008 Aug; 3(8):e2994. PubMed ID: 18714348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
    Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
    J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.
    Zhao X; Rødland EA; Sørlie T; Vollan HK; Russnes HG; Kristensen VN; Lingjærde OC; Børresen-Dale AL
    BMC Cancer; 2014 Mar; 14():211. PubMed ID: 24645668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
    Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
    J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
    Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
    Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.